Incanthera ends pharmaceutical agreement to focus on skincare brand

(Alliance News) - Incanthera PLC on Friday said it has ended an agreement with Limeway Pharma ...

Alliance News 28 March, 2025 | 3:42PM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - Incanthera PLC on Friday said it has ended an agreement with Limeway Pharma Design Ltd as it focuses on its Skin + Cell skincare range.

The Manchester, England-based developer of technologies in dermatology and oncology said it has finished product in stock ready for immediate distribution for its luxury skincare brand Skin + Cell.

The firm said it was focusing on monetising the range due to market interest and the short lead time for distribution, ahead of developing its skin solar keratosis treatment and skin melanoma prevention programme called Sol.

As a result, Incanthera has terminated the product development and licensing agreement with Limeway Pharma from March 2018.

The two companies have agreed to cross licence patent rights on a royalty free basis for future independent work on solar keratosis and skin melanoma.

Incanthera said it can continue to develop the Sol project in future.

Shares in Incanthera were down 12% to 10.75 pence on the Aquis Exchange on Friday afternoon.

By Michael Hennessey, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2025 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Incanthera PLC Ordinary Shares 10.75 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures